Adagrasib Combo Therapy for Lung Cancer
(202200050434 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
Study CA239-0010 is an open-label, Phase 2 clinical trial evaluating the clinical efficacy of adagrasib in combination with pembrolizumab and chemotherapy in the first-line setting for patients with advanced NSCLC with TPS ≥ 1%, TPS \<50% and KRAS G12C mutation
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you have had prior therapy targeting the KRASG12C mutation or certain treatments for advanced NSCLC, you may not be eligible to participate.
What makes the drug Adagrasib unique for lung cancer treatment?
Adagrasib is unique because it specifically targets the KRAS G12C mutation found in some lung cancers, locking the mutant protein in an inactive state to stop cancer growth. It is taken orally and has shown promising response rates with lower liver toxicity compared to other similar treatments.12345
Who Is on the Research Team?
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Are You a Good Fit for This Trial?
This trial is for adults with advanced non-small cell lung cancer (NSCLC) that has a specific mutation called KRAS G12C. Participants must have measurable disease and varying levels of PD-L1 expression, depending on the cohort they fall into. They should not have received certain prior treatments for NSCLC or have active brain metastases.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive adagrasib in combination with pembrolizumab and chemotherapy
Safety Lead In (SLI)
Participants are monitored for dose-limiting toxicities during the initial treatment cycle
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Adagrasib
- Pembrolizumab
Adagrasib is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mirati Therapeutics Inc.
Lead Sponsor
Dr. Charles M. Baum
Mirati Therapeutics Inc.
Chief Executive Officer since 2023
MD, PhD
Dr. Joseph Leveque
Mirati Therapeutics Inc.
Chief Medical Officer since 2021
MD